Professor Kimme Hyrich MD PhD FRCPC

Photograph of Kimme Hyrich

Professor of Epidemiology

Arthritis Research UK Centre for Epidemiology
Centre for Musculoskeletal Research
Institute of Inflammation and Repair
The University of Manchester
Manchester Academic Health Science Centre
Room 2.809 Stopford Building
Oxford Road
Manchester
M13 9PT
 

PA - Gillian Amroon - Telephone - 0161 275 5044 - E-mail - Gillian.Amroon@manchester.ac.uk

Role

I am a Reader in Rheumatic Disease Epidemiology in the Arthritis Research UK Centre for Epidemiology, part of the Centre for Musculoskeletal Research and a Consultant Rheumatologist in the Kellgren Centre for Rheumatology at Central Manchester University Hospitals NHS Foundation Trust. 

I am also the Programme Director for the MRes in Medical Sciences (for intercalatintg medical students and NIHR Academic Clinical Fellows) and Epidemiology Module Lead for the MSc in Clinical Rheumatology.

I am a clinical epidemiologist and my main research interests are understanding the short and longterm outcomes in adult and childhood inflammatory arthritis, including a greater understanding of the role treatments play in these outcomes.

Memberships of Committees and Professional Bodies

Methodological Knowledge

Epidemiology and biostatistics including analysis of longterm observational cohort studies.

Teaching

  • MRes in Medical Sciences -  Programme Director
  • Supervision of higher level degress (MRes, MSc and PhD)
  • Manchester Medical School - Academic Advisor
  • Epidemiology Module Lead - MSc in Clinical Rheumatology

Biography

I completed my Bachelors of Science and medical degree at the University of Manitoba in Canada. This was followed by training in internal medicine in Winnipeg, Canada and a fellowship in rheumatology at the University of Toronto. I subsequently worked as an Arthritis Society of Canada/CIHR Research Fellow at the Arthritis Research UK (formerly arc) Epidemiology Unit in Manchester, being awarded my PhD in 2005. I am currently a Reader in Rheumatic Disease Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary, Manchester, UK.

My main research interests centre on outcomes in inflammatory arthritis, with a particular focus on pharmacoepidemiology. I am a principal investigator for the British Society for Rheumatology Biologics Register (BSRBR), which is prospectively collecting information on all patients receiving biologic therapy for a rheumatic disease throughout the United Kingdom. Work from this project has assessed the real-world efficacy of anti-TNF agents for rheumatoid arthritis as well as predictors of response and the risk of adverse events, including infection and myocardial infarction. My research in paediatrics includes the Childhood Arthritis Prospective Study (CAPS), an inception cohort which is studying both short and long-term outcomes in children diagnosed in the UK with juvenile idiopathic arthritis and 2 biologic registers in children: the Arthritis Research UK funded Safety and Efficacy of Biologics in Children (Extended Biologics Study) and the BSPAR Etanercept Register, which is focusing on the short and long-term safety of the use of biologic drugs in children with arthritis.

I supervise a number of PhD and Masters students working on these and related projects.

Qualifications

  • Bachelor of Science (1992) - University of Manitoba, Canada
  • MD (1996) - University of Manitoba, Canada
  • Fellow of the Royal College of Physicians of Canada (General Medicine and Rheumatology) (2000)
  • PhD (2005) - University of Manchester, UK
  • Associate Member - Royal College of Physicians of Edinburgh (2005)

Collaborators and affiliated staff

  • Deborah Symmons (Manchester)
  • Anne Barton (Manchester)
  • Wendy Thomson (Manchester)
  • Michael Beresford (Liverpool)
  • Eileen Baildam (Liverpool)
  • Lucy Wedderburn (London)
  • Joyce Davidson (Glasgow)
  • Helen Foster (Newcastle)
  • Kath Watson (Manchester)
  • Anja Strangfeld (Berlin)
  • Angela Zink (Berlin)
  • Johan Askling (Stockholm)
  • Tim Beukleman (Birmingham, USA)
  • James Galloway (London)

Selected publications

2015

  • Bluett, J., Morgan, C., Barton, A., BRAGGSS, B., Thurston, L., Plant, D., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J. & Cordingley, L (2015). Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford), 54(3), 494-499. eScholarID:234413 | PMID:25213131 | DOI:10.1093/rheumatology/keu358
  • Davies, R., Southwood, T., Kearsley-Fleet, L., Lunt, M., Hyrich, K. & ETN), B (2015). Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept. Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol, [Epub ahead of print], eScholarID:265101 | PMID:25989609 | DOI:10.1002/art.39197
  • Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich KL, Barton A; BRAGGSS. (2015). Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheum, [Epub ahead of print], eScholarID:263348 | DOI:10.1002/art.39169
  • Kearsley-Fleet, L., Hyrich, K., Davies, R., Lunt, M. & Southwood, T (2015). Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford), [E-pub ahead of print], eScholarID:258962 | PMID:25638806 | DOI:10.1093/rheumatology/keu489
  • Kearsley-Fleet, L., Závada, J., Hetland, M., Nordström, D., Aaltonen, K., Listing, J., Zink, A., Gati, T., Rojkovich, B., Iannone, F., Gremese, E., van Riel, P., van de Laar, M., Lie, E., Kvien, T., Canhão, H., Fonseca, J., Rotar, Z., Loza, E., Carmona, L., Askling, J., Johansson, K., Finckh, A., Dixon, W. & Hyrich, K (2015). The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford), 54(6), 1074-1079. eScholarID:242324 | PMID:25433042 | DOI:10.1093/rheumatology/keu446
  • Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. & Hyrich, K (2015). Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis, 74(6), 1087-1093. eScholarID:223617 | PMID:24685910 | DOI:10.1136/annrheumdis-2013-204851
  • Morgan,C.; McBeth,J.; Cordingley,L.; Watson,K.; Hyrich,K.L.;Symmons,D.P.M.;Bruce,I.N. (2015). The Influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: A study in the biologics era. Rheumatology (Oxford), [Epub ahead of print], eScholarID:262169
  • Radner, H., Dixon, W., Hyrich, K. & Askling, J (2015). Consistency and utility of data items across European rheumatoid arthritis clinical cohorts and registers. Arthritis Care Res (Hoboken), [Epub ahead of print], eScholarID:264590 | PMID:25892245 | DOI:10.1002/acr.22602
  • Verstappen,S.M., Cobb,J., Foster,H.E., Fu,B., Baildam,E., Wedderburn,L.R., Davidson,J.E., Ioannou,J., Chieng,A., Hyrich,K.L., Thomson,W. (2015). Low socio-economic status is associated with high physical limitations and low illness self-perception in patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). Arthritis Care Res (Hoboken), 67(3), 382-389. eScholarID:232944 | PMID:25187470 | DOI:10.1002/acr.22466
  • Viatte, S., Plant, D., Han, B., Fu, B., Yarwood, A., Thomson, W., Symmons, D., Worthington, J., Young, A., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J., Raychaudhuri, S. & Barton, A (2015). Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA, 313(16), 1645-56. eScholarID:263992 | PMID:25919528 | DOI:10.1001/jama.2015.3435

2014

  • Bluett, et al (2014). Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J, 14(2), 171-175. eScholarID:201863 | PMID:23856853 | DOI:10.1038/tpj.2013.26
  • Hyrich, K. & Verstappen, S (2014). Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford), 53(8), 1377-1385. eScholarID:216516 | PMID:24352337 | DOI:10.1093/rheumatology/ket409
  • Mathews, R., Robinson, J., Battellino, M., Wong, C., Taylor, J., , B., Eyre, S., Churchman, S., Wilson, A., Isaacs, J., Hyrich, K., Barton, A., Plant, D., Savic, S., Cook, G., Sarzi-Puttini, P., Emery, P., Barrett, J., Morgan, A. & McDermott, M (2014). Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis, 73(6), 1202-1210. eScholarID:197153 | PMID:23687262 | DOI:10.1136/annrheumdis-2013-203276
  • Silva-Fernandez, L. & Hyrich, K (2014). Rheumatoid arthritis: When TNF inhibitors fail in RA-weighing up the options. Nat Rev Rheumatol, 10(5), 262-264. eScholarID:221933 | PMID:24614594 | DOI:10.1038/nrrheum.2014.34
  • Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & , B (2014). The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Ann Rheum Dis, 73(1), 252-255. eScholarID:197157 | PMID:23644671 | DOI:10.1136/annrheumdis-2012-203102
  • Yarwood,A.; Viatte S., Plant D., Morgan A.W., Isaacs J., Wilson A.G., Hyrich K., Eyre S., Barton A., Biologics_in_Rheumatoid_Arthritis_Genetics_and_Genomics. (2014). Testing the role of vitamin D in response to antitumour necrosis factor alpha therapy in a UK cohort: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 73(5), 938-940. eScholarID:234475 | DOI:10.1136/annrheumdis-2013-204443

2013

  • Coates, L., Tillett, W., Chandler, D., Helliwell, P., Korendowych, E., Kyle, S., McInnes, I., Oliver, S., Ormerod, A., Smith, C., Symmons, D., Waldron, N. & McHugh, N (2013). The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford), 52(10), 1754-1757. eScholarID:206101 | PMID:23887065 | DOI:10.1093/rheumatology/ket187
  • McErlane, F., Beresford, M., Baildam, E., Chieng, S., Davidson, J., Foster, H., Gardner-Medwin, J., Lunt, M., Wedderburn, L., Thomson, W., Hyrich, K. & Childhood_Arthritis_Prospective_Study_(CAPS), C (2013). Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis, 72(12), 1983-1988. eScholarID:186037 | PMID:23256951 | DOI:10.1136/annrheumdis-2012-202031
  • McErlane, F., Beresford, M., Baildam, E., Thomson, W. & Hyrich, K (2013). Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatology (Oxford), 52(11), 1941-1951. eScholarID:193908 | PMID:23630368 | DOI:10.1093/rheumatology/ket150

2009

  • Bowes, J, Potter, C, Gibbons, LJ, Hyrich, KL, Plant, D, BRAGGSS, Morgan, A, Wilson, A, Isaacs, J, Worthington, J, Barton, A. (2009). Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics, 19(4), 319-323. eScholarID:1d19079 | DOI:10.1097/FPC.0b013e328328d51f
  • Harrison MJ, Dixon WG, Watson KD, King YE, Groves R, Hyrich KL, Symmons D, BSRBR Control Centre Consortium. (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 68(2), 209-215. eScholarID:1d17129 | DOI:10.1136/ard.2007.087288

View all publications